Teva announces collaboration to commercialize formycon's biosimilar candidate to eylea® (aflibercept) in major parts of europe and in israel

Tel aviv, israel, jan. 13, 2025 (globe newswire) -- teva pharmaceuticals international gmbh, a subsidiary of teva pharmaceutical industries ltd. (nyse: and tase: teva) today announced that it has entered into a strategic collaboration with klinge biopharma gmbh (klinge) and formycon ag (fse: fyb) for the semi-exclusive commercialization of fyb203, formycon's biosimilar candidate to eylea® (aflibercept) in europe, excluding italy, and in israel.
TEVA Ratings Summary
TEVA Quant Ranking